Source-grounded facts extracted from Surgery Partners, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Surgery Partners, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal year 2026 at the 2026-06-05 meeting.
“The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Surgery Partners, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-05 meeting.
“The stockholders approved on a non-binding, advisory basis the compensation paid by the Company to its named executive officers, as disclosed in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 23, 2026.”
Surgery Partners, Inc. shareholders approved Election of Class II directors at the 2026-06-05 meeting.
“The stockholders elected each of the director nominees to serve as a Class II director until the Company’s 2029 annual meeting of stockholders and until each such successor has been elected and qualified.”
Surgery Partners, Inc. reported Full year 2026 results: revenue $3.35 billion to $3.45 billion. Guidance reaffirmed.
“The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million.”
Surgery Partners, Inc. reported first quarter ended March 31, 2026 results: revenue $810.9 million, net income $35.9 million. Guidance reaffirmed.
“return the business to consistent growth, while delivering on long-term shareholder value.” First Quarter 2026 Results Revenues for the first quarter of 2026 increased 4.5% to $810.9 million compared to $776.0 million for the first quarter of 2025. Same-facility revenues for the first quarter of 2026 increased 4.4% as compared to the same period in prior year, with a”
Surgery Partners, Inc. entered into Third Supplemental Indenture with Wilmington Trust, National Association valued at $425.0 million aggregate principal amount of 7.250% Senior Notes due 2032 (effective 2025-12-16).
“On December 16, 2025, Surgery Center Holdings, Inc. (the “Issuer”), a wholly-owned subsidiary of Surgery Partners, Inc. (the “Company”), issued an additional $425.0 million aggregate principal amount of 7.250% Senior Notes due 2032 (the “Notes”). In connection with the closing of the offering of the Notes, the Issuer and the direct and indirect subsidiaries of the Issuer that guarantee the Notes entered into a Third Supplemental Indenture, dated as of December 16, 2025 (the “Supplemental Indenture”), with Wilmington Trust, National Association, as trustee, to the indenture, dated as of April 10, 2024 (the “Base Indenture” and, as amended and supplemented, collectively with the Supplemental Indenture, the “Indenture”).”
Surgery Partners, Inc. incurred senior notes of $425.0 million at 7.250% maturing due 2032.
“issued an additional $425.0 million aggregate principal amount of 7.250% Senior Notes due 2032”
Surgery Partners, Inc. incurred credit facility of Aggregate principal amount of $1,383 million for 2025 Refinancing Term Loans; revolving credit commitments refinanced in with Jefferies Finance LLC and other financial institutions at Term SOFR plus 2.50% per annum or alternate base rate plus 1.50% per annum maturing December 19, 2030 for term loans; December 19, 2028 for revolving loans.
“The Second Amendment amended the Credit Agreement to, among other things, (i) provide for a new tranche of term loans under the Credit Agreement in an aggregate principal amount of $1,383 million (the “2025 Refinancing Term Loans”), which 2025 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Second Amendment), and (ii) refinance in full all of the existing revolving credit commitments and outstanding revolving loans under the Credit Agreement (as in effect immediately prior to the Second Amendment), all as further set forth in the Second Amendment.”
Surgery Partners, Inc. reported full year 2024 results: revenue at least $3.05 billion. Guidance raised.
“The Company raised its outlook for 2024 revenues to be at least $3.05 billion and projects 2024 Adjusted EBITDA to be at least $505 million.”
Surgery Partners, Inc. reported three months ended March 31, 2024 results: revenue $717.4 million, net income -$12.4 million.
“• Revenues increased 7.7% to $717.4 million compared to the prior year period ◦ Same-facility revenues increased 10.2% • Net loss attributable to Surgery Partners, Inc. was $12.4 million”
Surgery Partners, Inc. terminated Existing Indentures (2027 Notes Indenture and 2025 Notes Indenture) with Wilmington Trust, National Association valued at Satisfaction and discharge of 10.000% Senior Notes due 2027 and 6.750% Senior Notes due 2025 (effective 2024-04-10).
“In connection with the issuance of the Notes, on April 10, 2024, the Issuer effected a satisfaction and discharge of those certain Indentures, dated as of April 11, 2019 (the “2027 Notes Indenture”), among the Issuer, the guarantors party thereto from time to time and the Trustee, governing the Issuer’s 10.000% Senior Notes due 2027 (the “2027 Notes”) and that certain Indenture, dated as of June 30, 2017 (the “2025 Notes Indenture” and together with the 2027 Notes Indenture, the “Existing Indentures”), among the Issuer, the guarantors party thereto from time to time and the Trustee, governing the Issuer’s 6.750% Senior Notes due 2025 (the “2025 Notes” and together with the 2027 Notes, the “Existing Notes”).”
Surgery Partners, Inc. entered into Indenture dated April 10, 2024 with Wilmington Trust, National Association valued at $800,000,000 7.250% senior unsecured notes due 2032 (effective 2024-04-10).
“On April 10, 2024, Surgery Center Holdings, Inc. (the “Issuer”), a wholly owned subsidiary of Surgery Partners, Inc. (the “Registrant”), completed the issuance and sale of $800.0 million in gross proceeds of the Issuer’s 7.250% senior unsecured notes due 2032 (the “Notes”).”
Surgery Partners, Inc. updated its fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).
“On February 26, 2024, Surgery Partners, Inc. issued a press release announcing results for the fourth quarter and full year ended December 31, 2023.”
Surgery Partners, Inc. updated its 2024 guidance (initiated).
“In addition, the Company projects 2024 Adjusted EBITDA to be greater than $495 million.”
Surgery Partners, Inc. reported 2023 results: revenue approximately $2.75 billion. Guidance reaffirmed.
“Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion.”
Surgery Partners, Inc. incurred revolving credit of $703.75 million with Jefferies Finance LLC at Term SOFR plus 3.25% per annum maturing December 19, 2028.
“providing for a $1,400 million senior secured term loan (the “Term Loan”) and a $703.75 million revolving credit facility (the “Revolver””
Surgery Partners, Inc. incurred term loan of $1,400 million with Jefferies Finance LLC at Term SOFR plus 3.50% per annum maturing December 19, 2030.
“r the “Company”), entered into a credit agreement with Jefferies Finance LLC, as administrative agent and collateral agent, and the other financial institutions party thereto from time to time (the “Credit Agreement”), providing for a $1,400 million”
Surgery Partners, Inc. entered into Credit Agreement with Jefferies Finance LLC, as administrative agent and collateral agent, and the other financial institutions party thereto from time to time valued at $1,400 million senior secured term loan and a $703.75 million revolving credit facility (effective 2023-12-19).
“entered into a credit agreement with Jefferies Finance LLC, as administrative agent and collateral agent, and the other financial institutions party thereto from time to time (the "Credit Agreement"), providing for a $1,400 million senior secured term loan (the "Term Loan") and a $703.75 million revolving credit facility”
Surgery Partners, Inc. reported 2023 results: revenue approximately $2.75 billion. Guidance raised.
“The Company raised projected 2023 Adjusted EBITDA to a range of $436 million to $440 million and anticipates revenue at approximately $2.75 billion.”
Surgery Partners, Inc. reported year-to-date 2023 results: revenue $2,007.9 million, net income $10.9 million.
“respectively, compared to $25.0 million and $96.2 million, respectively, for the same period last year. Year-to-Date 2023 Results Revenues year-to-date 2023 increased 9.6% to $2,007.9 million from $1,832.2 million for the 2022 period. Days adjusted same-facility revenues for year-to-date 2023 increased 10.6% from the same period last year, with an increase in revenue”
Surgery Partners, Inc. reported third quarter ended September 30, 2023 results: revenue $674.1 million, net income $4.9 million.
“Partners" or the "Company"), a leading operator of surgical facilities, today announced financial results for the third quarter ended September 30, 2023. • Revenues were $674.1 million representing 8.6% growth • Days Adjusted Same-facility revenues increased 14.2% • Net loss attributable to Surgery Partners was $4.9 million • Adjusted EBITDA was $105.5 million,”
Surgery Partners, Inc. reported for fiscal year 2023 results: revenue greater than $2.75 billion. Guidance raised.
“Full year Adjusted EBITDA guidance raised to greater than $435 million, revenue reaffirmed at greater than $2.75 billion, inclusive of the cyber event, and free cash flow reaffirmed at greater than $140 million.”
Surgery Partners, Inc. reported for the second quarter ended June 30, 2023 results: revenue Revenues were $667.6 million, net income Net income attributable to Surgery Partners was $18.9 million.
“Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced financial results for the second quarter ended June 30, 2023. • Revenues were $667.6 million representing 8.5% growth and are inclusive of an $8 million cyber event headwind • Same-facility revenues increased 8.3% on an unadjusted basis and approximately 10% adjusting for the cyber event • Non-consolidated minority interest revenue increased by over 30% • Net income attributable to Surgery Partners was $18.9 million • Adjusted EBITDA was $100.2 million, representing 16.4% growth • Adjusted EBITDA margin improved by over 100 basis points year-over-year to 15.0% • Combined, consolidated and unconsolidated surgical case volume grew 5%”
Surgery Partners, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-01 meeting.
“Proposal 4: Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2023. The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions 122,861,637 40,051 4,538”
Surgery Partners, Inc. shareholders approved Advisory vote on frequency of future executive compensation votes at the 2023-06-01 meeting.
“Proposal 3: Advisory vote on frequency of future executive compensation votes. The stockholders approved on a non-binding, advisory basis that a non-binding, advisory stockholder vote on the compensation paid to the Company's named executive officers shall occur annually. The results of the vote were as follows: One Year Two Years Three Years Abstentions Broker Non-Votes 120,851,075 6,631 575,732 9,290 1,463,498”
Surgery Partners, Inc. shareholders approved Advisory vote on executive compensation at the 2023-06-01 meeting.
“Proposal 2: Advisory vote on executive compensation. The stockholders approved on a non-binding, advisory basis the compensation paid by the Company to its named executive officers, as disclosed in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 20, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 118,127,561 3,307,178 7,989 1,463,498”
Surgery Partners, Inc. shareholders approved Election of Class II directors at the 2023-06-01 meeting.
“Proposal 1: Election of Class II directors. The stockholders elected each of the director nominees to serve as a Class II director until the Company’s 2026 annual meeting of stockholders and until each such successor has been elected and qualified. Each of the nominees was a current Class II director of the Company who was re-elected. The results of the vote were as follows: Name Votes For Votes Withheld Broker Non-Votes Patricia A. Maryland, Dr.PH 107,534,448 13,894,991 1,476,787 T. Devin O'Reilly 105,594,699 15,834,740 1,476,787 Brent Turner 114,973,075 6,469,653 1,463,498”
Surgery Partners, Inc. updated its full year 2023 guidance (raised).
“The Company raises projected 2023 Adjusted EBITDA to be greater than $430 million.”
Surgery Partners, Inc. reported first quarter ended March 31, 2023 results: revenue $666.2 million, net income $(24.9) million. Guidance raised.
“a leading provider of surgical services, today announced financial results for the first quarter ended March 31, 2023. • Revenue increased 11.7% from the prior year period to $666.2 million ◦ Same-facility revenue increasing 10.3% • Net loss attributable to Surgery Partners, Inc. was $24.9 million ◦ Adjusted EBITDA of $90.1 million; 17% greater than the prior year”
Surgery Partners, Inc. reported full year 2023 results: revenue greater than $2.75 billion. Guidance raised.
“The Company projects 2023 revenues to be greater than $2.75 billion, and projects 2023 Adjusted EBITDA to be greater than $425 million.”
Surgery Partners, Inc. reported financial results for full year ended December 31, 2022.
“Revenue for 2022 increased 14.1% to $2,539.3 million from $2,225.1 million in 2021.”
Surgery Partners, Inc. reported financial results for fourth quarter ended December 31, 2022.
“Revenue for the fourth quarter of 2022 increased 15.9% to $707.1 million from $610.2 million for the fourth quarter of 2021.”
Surgery Partners, Inc. reported the fiscal year ended December 31, 2022 results: revenue $2.50 billion to $2.55 billion. Guidance reaffirmed.
“Based on results through November 2022, the Company is re-affirming its 2022 Adjusted EBITDA guidance of $375 million to $385 million and its 2022 Revenue guidance of $2.50 billion to $2.55 billion.”
Surgery Partners, Inc. entered into Purchase Agreement with an affiliate of its controlling shareholder ("Bain Capital") valued at $225 million (effective 2022-11-21).
“In connection with the Public Offering, the Company undertook a concurrent private placement (the “ Private Placement ”) of $225 million of its common stock to an affiliate of its controlling shareholder (“ Bain Capital ”). In connection with the Private Placement, the Company and Bain Capital entered into a stock purchase agreement (the “ Purchase Agreement ”) pursuant to which the Company has agreed to sell and issue to Bain Capital, up to an aggregate of 9,183,673 shares of the Company’s common stock.”
Surgery Partners, Inc. reported Full year 2022 results: revenue $2.5 billion to $2.55 billion. Guidance reaffirmed.
“The Company reaffirms projected 2022 Adjusted EBITDA of $375 million to $385 million and anticipates revenue in the range of $2.5 billion to $2.55 billion.”
Surgery Partners, Inc. reported Third quarter ended September 30, 2022 results: revenue $620.6 million, net income -$25.0 million.
“Revenue for the third quarter of 2022 increased 11.0% to $620.6 million from $559.2 million for the third quarter of 2021. Same-facility revenues for the third quarter of 2022 increased 5.1% from the same period last year, with an increase in revenue per case of 1.8% and an increase in same-facility cases of 3.3%. For the third quarter of 2022, the Company’s net 1 loss attributable to common stockholders and Adjusted EBITDA was $25.0 million and $96.2 million, respectively, compared to $22.9 million and $76.4 million, respectively, for the same period last year.”
David T. Doherty was appointed as Executive Vice President and Chief Financial Officer at Surgery Partners, Inc..
“On January 10, 2022, the Company announced the appointment of David T. Doherty to serve as Executive Vice President and Chief Financial Officer of the Company, effective as of February 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.